Madrigal Pharmaceuticals, Inc.

Roivant has promised investors it will spend some of its impressive cash stockpile on buying new assets. But midway into the year, no deals have been signed. CEO Matt Gline, in an interview at the com

There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase

Following GSK’s $1.2bn acquisition of privately held Boston Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis (MASH) candidate efimosfermin on 14 May, the industry is wondering what re

Neurocrine Updates On Crenessity Launch Neurocrine Biosciences announced encouraging early sales for its new commercial product, Crenessity (crinecerfont), in its first full quarter of launch. Crene